Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Immunological Reviews · 2023-09 · 318 (1) · 157-166
DOI: 10.1111/imr.13249 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 20.07.2023. Verfasst von Rachel S Goodman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Colorectal Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Burroughs Wellcome Fund, National Cancer Institute.
Abstract (Originalsprache)
Immune checkpoint inhibitors have transformed cancer therapy, but their optimal use is still constrained by lack of response and toxicity. Biomarkers of response may facilitate drug development by allowing appropriate therapy selection and focusing clinical trial enrollment. However, aside from PD‐L1 staining in a subset of tumors and rarely mismatch repair deficiency, no biomarkers are routinely used in the clinic. In addition, severe toxicities may cause severe morbidity, therapy discontinuation, and even death. Here, we review the state of the field with a focus on our research in therapeutic biomarkers and toxicities from immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Medicine, Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Douglas B Johnson
Förderung
- NCI NIH HHS
- Burroughs Wellcome Fund
- National Cancer Institute
Zitieren
APA
Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023). Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunological Reviews, 318(1), 157-166. https://doi.org/10.1111/imr.13249
Vancouver
Goodman RS, Jung S, Balko JM, Johnson DB. Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunological Reviews. 2023;318(1):157-166. doi:10.1111/imr.13249
BibTeX
@article{Goodman2023,
author = {Goodman, Rachel S and Jung, Seungyeon and Balko, Justin M and Johnson, Douglas B},
title = {Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities},
journal = {Immunological Reviews},
year = {2023},
volume = {318},
number = {1},
pages = {157--166},
doi = {10.1111/imr.13249}
}
EUVIMED